
Highland Capital Large Capital Growth ETF
Highland Capital Large Capital Growth ETF (AQLG) Price & Chart
AQLG ETF Chart & Stats
- Day’s Range
- $25.96 - $25.96
- 52-Week Range
- $24.79 - $26.98
- Previous Close
- $25.67
- Volume
- 8
- Average Volume (3M)
- 24
- AUM
- 75.63M
- NAV
- 25.66
- Expense Ratio
- 0.65%
- Holdings Count
- 130
- Beta
- 0.77
- Inception Date
- Jun 08, 2026
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 2,942,716
- Standard Deviation
- N/A
ETF Overview
Highland Capital Large Capital Growth ETF
Highland Capital Large Capital Growth ETF (AQLG) is an actively managed ETF focused on delivering long‑term capital appreciation by investing primarily in large‑capitalization U.S. companies exhibiting growth characteristics. The fund uses a disciplined multi‑factor investment process that combines fundamental analysis (earnings and revenue trends, profitability and cash‑flow metrics, and balance‑sheet quality) with technical signals (momentum, price trends and relative strength) to score, rank and select securities across the large‑cap universe. That process produces a concentrated, high‑conviction portfolio that typically emphasizes companies with above‑average revenue and earnings growth, solid quality metrics and positive price momentum. Sector weights often skew to growth‑oriented areas such as technology, consumer discretionary and health care, but the active approach permits managers to adjust sector and stock exposures as valuation or macro opportunities emerge. Risk controls and regular rebalancing are applied to manage concentration and downside risk. As an ETF, AQLG offers the intraday liquidity and structural efficiencies of an exchange‑traded vehicle while providing the flexibility of active stock selection. It is designed for investors seeking a large‑cap growth sleeve—either as a core growth allocation or as a tactical complement to a diversified equity portfolio—who are comfortable with the higher volatility and valuation sensitivity that typically accompany growth‑oriented equity strategies.
- Asset Class
- Equity
- Region
- North America
- Issuer
- HCM
- Index Tracked
- No Underlying Index
- Ticker Symbol
- AQLG
AQLG ETF News



Abbvie ($ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s official study, “A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease











